Navigation Links
OncoGenex Reports Second Quarter 2009 Financial Results
Date:8/6/2009

    Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the second quarter and six months ended June 30, 2009 and reviewed the Company's highlights for the second quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

The loss attributable to common shareholders for the second quarter increased to $4.6 million from $2.9 million in 2008. For the six months ended June 30, 2009 the loss attributable to common shareholders increased to $7.0 million from $5.4 million in 2008.

Research and development expenses for the second quarter increased to $3.6 million from $1.1 million in 2008. For the six months ended June 30, 2009 research and development expenses increased to $5.3 million from $2.0 million in 2008. The increases in 2009 were primarily due to manufacturing costs incurred in the first six months of 2009 associated with the development of our product candidates OGX-011 and OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first six months of 2008 was a Scientific Research and Development (SRED) claim, which offset R D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Silver Industryā€¯ is a professional and in-depth study on ... Global and China. , The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... Neurognostics , a home-grown Milwaukee medical device company, ... the first to take advantage of Wisconsin's new tax credits ... of an investment. , ,Neurognostics oversubscribed on its $1 million ... CEO af Neurognostics. As a tech-based research and development company, ...
... produce a single venture capital deal from January through March ... , ,Venture capitalists in the state said that the lack ... the state, though it is another reminder that capital is ... Wisconsin's investments have come erratically, sometimes adding up to around ...
... enough. Researchers at the University of Wisconsin-Madison, among other ... networked computers that share tasks such as analyzing the ... Schwartz are working with the Grid Laboratory of ... system used is Condor, software developed in-house to grab ...
Cached Biology Technology:Milwaukee firm among first to use Act 255 tax credits in investor pitch 2Milwaukee firm among first to use Act 255 tax credits in investor pitch 3Milwaukee firm among first to use Act 255 tax credits in investor pitch 4Money Tree survey shows lull in Wisconsin venture capital deals 2Money Tree survey shows lull in Wisconsin venture capital deals 3
(Date:7/13/2014)... in French . ... research project, led by the Research Institute of the ... a new oral medication is showing significant progress in ... Until now, this inherited retinal disease that causes visual ... remained untreatable. The study is published today in the ...
(Date:7/13/2014)... the prospect of more effective treatments for cachexia, a ... half of all cancer patients, raising their risk of ... Many strategies have been tried to reverse the condition, ... potentially life-saving treatments, but none have had great success. ... edition of Nature , led by Bruce Spiegelman, ...
(Date:7/11/2014)... from the Wildlife Conservation Society shows that no-take ... valuable species such as lobster, conch, and fish ... nearby reef areas. , The reporttitled "Review of ... of research literature from no-take areas around the ... Dahlgren, a recognized expert in marine protected areas ...
Breaking Biology News(10 mins):MUHC researcher unveils novel treatment for a form of childhood blindness 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2
... critical cellular activities in plants and animals by using ... to learn from nature, a team of Northwestern University ... Air Force Office of Scientific Research to study and ... civilian applications. The grant is part of the ...
... Marine Animal Population , Edited by David J. ... http://shop.earthscan.co.uk/ProductDetails/mcs/productID/821 , Violent confrontations on the ... the intense hunt for sponges on Floridas fragile coral ... sponges themselves. Human harvesters not only depleted the sponge ...
... elderly residents and giving them fewer sleeping pills could ... nursing home units published in the January issue of ... by the Karolinska Institutet, Sweden, analysed 2,343 reported falls ... how they related to fall risk assessments and the ...
Cached Biology News:Team of chemists receives $5 million grant to develop enzyme mimics 2Oceans Past: A Guide to Oceans Future 2Oceans Past: A Guide to Oceans Future 3Oceans Past: A Guide to Oceans Future 4Oceans Past: A Guide to Oceans Future 5Oceans Past: A Guide to Oceans Future 6Selective restraints and reduced medication could reduce nursing home falls says 4-year study 2
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
... Immunogen: Recombinant protein ... region of human ubiquilin. ... the human ubiquilin protein. ... control: 293 cells). ...
...
Biology Products: